1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Renal Cell Carcinoma: KOL Insight

Renal Cell Carcinoma: KOL Insight

  • February 2015
  • -
  • Firstword Pharma

Will new checkpoint inhibitors revive immunotherapy in RCC?

Renal Cell Carcinoma: KOL Insight offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma and the drug discovery community. Gain insights on what leading clinicians think about current treatment options, new therapies, the critical role of clinical research and the factors that influence oncologists’ prescribing decisions.

With the expected approval and launch of PD-1 inhibitors such BMS’ Opdivo (nivolumab) the options for first- and second-line treatment of RCC are expected to widen over time and impact currently available therapies. While initially these new products will be launched as monotherapies for second-line treatment there is wide anticipation that, in combination, they will ultimately take a commanding role in first-line treatment.

This report gives insights into when and why clinicians will use these new therapies and how it influences their prescribing decisions. In addition, readers will gain insights on which product combinations are most favoured and why, which products are most likely to be affected as the new treatment paradigm takes shape and the strategic lessons for drug discovery and development companies.

Therapy Trends reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

Top Takeaways

Formulate effective strategies for clinician communication by understanding KOL concerns
Find key areas for strategic and tactical action by understanding the important factors affecting the RCC sector
Design clinical trials which are more likely to lead to strong product positioning (e.g. more effective comparator, population and endpoint selection)
Identify companies/products that are likely to move down the treatment pathway as new therapies gain market share
Make more informed decisions about which R&D programmes warrant investment or discontinuation
Position your early stage research and licencing plans to exploit future competitor weaknesses
Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and their likely outcomes (CheckMate-025, METEOR, IMPRINT, ADAPT, SWITCH-II, CROSS-J-RCC, FLIPPER, ASSURE, S-TRAC, PROTECT, and ATLAS)
Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions
Evaluate the changing competitive landscape and identify solutions that aid KOLs in their practice
Review next generation development approaches and identify opportunity areas

Gain Answers to Key Questions

What clinical advantages do KOLs see in GSK’s VEGF TKI Votrient (pazobanib) over Pfizer’s Sutent (sunitinib) and how might this play out?
What head-to-head clinical trials would help KOLs when making second line treatment decisions?
What are the future prospects for mTOR inhibitors such as Novartis’Afinitor (everolimus) and why might KOL’s prefer Pfizer’s Inlyta and the VEGF TKI options?
What cost/benefit consideration should BMS consider for Opdivo in Europe?
How might the availability of checkpoint inhibitors give a boost to Roche’s Avastin (bevacizumab)?
What is the potential of Argos’ AGS-003 and Inmatics’ renal cancer vaccine IMA901 – is their window of opportunity gone?
How might the future treatment landscape and late-stage hopefuls influence drug development companies when making their portfolio decisions?

Key Opinion Leaders

North America

Michael B. Atkins, MD - Georgetown University School of Medicine, Washington, DC
Robert Figlin, MD, FACP Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, CA
James J. Hsieh, MD, PhD, Memorial Sloan Kettering Cancer Center, NY
Robert J. Motzer, MD, Memorial Sloan Kettering Cancer Center, NY Brian Rini, MD, Case Western Reserve University,OH


Bernard Escudier, MD Institut Gustave Roussy, France Emilio Esteban Hospital Universitario Central de Asturias, Oviedo, Spain
Camillo Porta, MD, University of Pavia, Italy Prof
Thomas Powles, MBBS, MRCP, MD Barts Cancer Institute, UK
Cora Sternberg, MD Institut Gustave Roussy, France
2 anonymous German KOLs

Report Features

Insightful drug and development analysis with “real world” opinions of leading US and European KOLs not available elsewhere
Detailed and candid views on the future positioning and competitiveness of current and late-stage targeted and immune therapies
Essential insights which answer critical business questions in the RCC market for industry marketers, drug discovery/developer companies, clinical researchers and business planners
A comprehensive horizon scan for both branded and drug development companies

Update Bulletins Offer Ongoing Benefitss

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, February 2015.
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date

Table Of Contents

Renal Cell Carcinoma: KOL Insight
1.Executive Summary
2.Research Objectives
3.Research Focus
4.Current treatment landscape
5.2.1.Proleukin (aldesleukin; Prometheus Laboratories/Novartis)
5.2.2.Interferon alpha (various brands)
5.3.VEGF antibo

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.